The polypill: A potential global solution to cardiovascular disease

Caroline Nguyen, Angela Cheng-Lai

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Despite groundbreaking advances in health care, cardiovascular disease (CVD) remains the leading cause of death and disability worldwide, making it one of the most pressing global health issues to face the modern world. In 2002, Wald and Law proposed the concept of the polypill as a potential solution to this global health epidemic. The polypill represents a powerhouse pill that would consist of a combination of several key medications commonly prescribed for CVD prevention, such as a statin, diuretic, beta blocker, or angiotensin converting enzyme inhibitor, in one pill. It was suggested that it could be a novel, tactical measure in the approach to CVD prevention in that it greatly simplifies the healthcare delivery system. Not only does it increase medication compliance for those currently receiving health care, but it also has the potential to access those in underserved healthcare sectors of the world, primarily low- and middle-income countries, which have been identified as areas of highest CVD risk. A major drawback of the polypill is that there are limited data demonstrating its safety and efficacy in the prevention of cardiovascular morbidity and mortality. Thus far, research shows that the polypill has promise but needs to be approached with a few considerations, such as desired target patient population and formulation. This article will examine the published and ongoing studies associated with the polypill, outline the advantages and disadvantages of using the polypill as a global CVD prevention strategy, and discuss the design and availability of the polypill in the United States.

Original languageEnglish (US)
Pages (from-to)49-54
Number of pages6
JournalCardiology in Review
Volume21
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Cardiovascular Diseases
Delivery of Health Care
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Health Care Sector
Medication Adherence
Health Services Needs and Demand
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Cause of Death
Morbidity
Safety
Mortality
Research
Global Health

Keywords

  • cardiovascular disease
  • fixed dose compound
  • global health care
  • Polycap
  • polypill
  • Red Heart Pill

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The polypill : A potential global solution to cardiovascular disease. / Nguyen, Caroline; Cheng-Lai, Angela.

In: Cardiology in Review, Vol. 21, No. 1, 01.2013, p. 49-54.

Research output: Contribution to journalArticle

@article{54c6a1e9806a483d86ee4b5a49a5f5f4,
title = "The polypill: A potential global solution to cardiovascular disease",
abstract = "Despite groundbreaking advances in health care, cardiovascular disease (CVD) remains the leading cause of death and disability worldwide, making it one of the most pressing global health issues to face the modern world. In 2002, Wald and Law proposed the concept of the polypill as a potential solution to this global health epidemic. The polypill represents a powerhouse pill that would consist of a combination of several key medications commonly prescribed for CVD prevention, such as a statin, diuretic, beta blocker, or angiotensin converting enzyme inhibitor, in one pill. It was suggested that it could be a novel, tactical measure in the approach to CVD prevention in that it greatly simplifies the healthcare delivery system. Not only does it increase medication compliance for those currently receiving health care, but it also has the potential to access those in underserved healthcare sectors of the world, primarily low- and middle-income countries, which have been identified as areas of highest CVD risk. A major drawback of the polypill is that there are limited data demonstrating its safety and efficacy in the prevention of cardiovascular morbidity and mortality. Thus far, research shows that the polypill has promise but needs to be approached with a few considerations, such as desired target patient population and formulation. This article will examine the published and ongoing studies associated with the polypill, outline the advantages and disadvantages of using the polypill as a global CVD prevention strategy, and discuss the design and availability of the polypill in the United States.",
keywords = "cardiovascular disease, fixed dose compound, global health care, Polycap, polypill, Red Heart Pill",
author = "Caroline Nguyen and Angela Cheng-Lai",
year = "2013",
month = "1",
doi = "10.1097/CRD.0b013e3182755429",
language = "English (US)",
volume = "21",
pages = "49--54",
journal = "Cardiology in Review",
issn = "1061-5377",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - The polypill

T2 - A potential global solution to cardiovascular disease

AU - Nguyen, Caroline

AU - Cheng-Lai, Angela

PY - 2013/1

Y1 - 2013/1

N2 - Despite groundbreaking advances in health care, cardiovascular disease (CVD) remains the leading cause of death and disability worldwide, making it one of the most pressing global health issues to face the modern world. In 2002, Wald and Law proposed the concept of the polypill as a potential solution to this global health epidemic. The polypill represents a powerhouse pill that would consist of a combination of several key medications commonly prescribed for CVD prevention, such as a statin, diuretic, beta blocker, or angiotensin converting enzyme inhibitor, in one pill. It was suggested that it could be a novel, tactical measure in the approach to CVD prevention in that it greatly simplifies the healthcare delivery system. Not only does it increase medication compliance for those currently receiving health care, but it also has the potential to access those in underserved healthcare sectors of the world, primarily low- and middle-income countries, which have been identified as areas of highest CVD risk. A major drawback of the polypill is that there are limited data demonstrating its safety and efficacy in the prevention of cardiovascular morbidity and mortality. Thus far, research shows that the polypill has promise but needs to be approached with a few considerations, such as desired target patient population and formulation. This article will examine the published and ongoing studies associated with the polypill, outline the advantages and disadvantages of using the polypill as a global CVD prevention strategy, and discuss the design and availability of the polypill in the United States.

AB - Despite groundbreaking advances in health care, cardiovascular disease (CVD) remains the leading cause of death and disability worldwide, making it one of the most pressing global health issues to face the modern world. In 2002, Wald and Law proposed the concept of the polypill as a potential solution to this global health epidemic. The polypill represents a powerhouse pill that would consist of a combination of several key medications commonly prescribed for CVD prevention, such as a statin, diuretic, beta blocker, or angiotensin converting enzyme inhibitor, in one pill. It was suggested that it could be a novel, tactical measure in the approach to CVD prevention in that it greatly simplifies the healthcare delivery system. Not only does it increase medication compliance for those currently receiving health care, but it also has the potential to access those in underserved healthcare sectors of the world, primarily low- and middle-income countries, which have been identified as areas of highest CVD risk. A major drawback of the polypill is that there are limited data demonstrating its safety and efficacy in the prevention of cardiovascular morbidity and mortality. Thus far, research shows that the polypill has promise but needs to be approached with a few considerations, such as desired target patient population and formulation. This article will examine the published and ongoing studies associated with the polypill, outline the advantages and disadvantages of using the polypill as a global CVD prevention strategy, and discuss the design and availability of the polypill in the United States.

KW - cardiovascular disease

KW - fixed dose compound

KW - global health care

KW - Polycap

KW - polypill

KW - Red Heart Pill

UR - http://www.scopus.com/inward/record.url?scp=84871756877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871756877&partnerID=8YFLogxK

U2 - 10.1097/CRD.0b013e3182755429

DO - 10.1097/CRD.0b013e3182755429

M3 - Article

C2 - 23018668

AN - SCOPUS:84871756877

VL - 21

SP - 49

EP - 54

JO - Cardiology in Review

JF - Cardiology in Review

SN - 1061-5377

IS - 1

ER -